Cargando…

CRISPR-Cas knockout of miR21 reduces glioma growth

Non-coding RNAs, including microRNAs (miRNAs), support the progression of glioma. miR-21 is a small, non-coding transcript involved in regulating gene expression in multiple cellular pathways, including the regulation of proliferation. High expression of miR-21 has been shown to be a major driver of...

Descripción completa

Detalles Bibliográficos
Autores principales: Nieland, Lisa, van Solinge, Thomas S., Cheah, Pike See, Morsett, Liza M., El Khoury, Joseph, Rissman, Joseph I., Kleinstiver, Benjamin P., Broekman, Marike L.D., Breakefield, Xandra O., Abels, Erik R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052041/
https://www.ncbi.nlm.nih.gov/pubmed/35572197
http://dx.doi.org/10.1016/j.omto.2022.04.001
_version_ 1784696699119206400
author Nieland, Lisa
van Solinge, Thomas S.
Cheah, Pike See
Morsett, Liza M.
El Khoury, Joseph
Rissman, Joseph I.
Kleinstiver, Benjamin P.
Broekman, Marike L.D.
Breakefield, Xandra O.
Abels, Erik R.
author_facet Nieland, Lisa
van Solinge, Thomas S.
Cheah, Pike See
Morsett, Liza M.
El Khoury, Joseph
Rissman, Joseph I.
Kleinstiver, Benjamin P.
Broekman, Marike L.D.
Breakefield, Xandra O.
Abels, Erik R.
author_sort Nieland, Lisa
collection PubMed
description Non-coding RNAs, including microRNAs (miRNAs), support the progression of glioma. miR-21 is a small, non-coding transcript involved in regulating gene expression in multiple cellular pathways, including the regulation of proliferation. High expression of miR-21 has been shown to be a major driver of glioma growth. Manipulating the expression of miRNAs is a novel strategy in the development of therapeutics in cancer. In this study we aimed to target miR-21. Using CRISPR genome-editing technology, we disrupted the miR-21 coding sequences in glioma cells. Depletion of this miRNA resulted in the upregulation of many downstream miR-21 target mRNAs involved in proliferation. Phenotypically, CRISPR-edited glioma cells showed reduced migration, invasion, and proliferation in vitro. In immunocompetent mouse models, miR-21 knockout tumors showed reduced growth resulting in an increased overall survival. In summary, we show that by knocking out a key miRNA in glioma, these cells have decreased proliferation capacity both in vitro and in vivo. Overall, we identified miR-21 as a potential target for CRISPR-based therapeutics in glioma.
format Online
Article
Text
id pubmed-9052041
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-90520412022-05-13 CRISPR-Cas knockout of miR21 reduces glioma growth Nieland, Lisa van Solinge, Thomas S. Cheah, Pike See Morsett, Liza M. El Khoury, Joseph Rissman, Joseph I. Kleinstiver, Benjamin P. Broekman, Marike L.D. Breakefield, Xandra O. Abels, Erik R. Mol Ther Oncolytics Original Article Non-coding RNAs, including microRNAs (miRNAs), support the progression of glioma. miR-21 is a small, non-coding transcript involved in regulating gene expression in multiple cellular pathways, including the regulation of proliferation. High expression of miR-21 has been shown to be a major driver of glioma growth. Manipulating the expression of miRNAs is a novel strategy in the development of therapeutics in cancer. In this study we aimed to target miR-21. Using CRISPR genome-editing technology, we disrupted the miR-21 coding sequences in glioma cells. Depletion of this miRNA resulted in the upregulation of many downstream miR-21 target mRNAs involved in proliferation. Phenotypically, CRISPR-edited glioma cells showed reduced migration, invasion, and proliferation in vitro. In immunocompetent mouse models, miR-21 knockout tumors showed reduced growth resulting in an increased overall survival. In summary, we show that by knocking out a key miRNA in glioma, these cells have decreased proliferation capacity both in vitro and in vivo. Overall, we identified miR-21 as a potential target for CRISPR-based therapeutics in glioma. American Society of Gene & Cell Therapy 2022-04-06 /pmc/articles/PMC9052041/ /pubmed/35572197 http://dx.doi.org/10.1016/j.omto.2022.04.001 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Article
Nieland, Lisa
van Solinge, Thomas S.
Cheah, Pike See
Morsett, Liza M.
El Khoury, Joseph
Rissman, Joseph I.
Kleinstiver, Benjamin P.
Broekman, Marike L.D.
Breakefield, Xandra O.
Abels, Erik R.
CRISPR-Cas knockout of miR21 reduces glioma growth
title CRISPR-Cas knockout of miR21 reduces glioma growth
title_full CRISPR-Cas knockout of miR21 reduces glioma growth
title_fullStr CRISPR-Cas knockout of miR21 reduces glioma growth
title_full_unstemmed CRISPR-Cas knockout of miR21 reduces glioma growth
title_short CRISPR-Cas knockout of miR21 reduces glioma growth
title_sort crispr-cas knockout of mir21 reduces glioma growth
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052041/
https://www.ncbi.nlm.nih.gov/pubmed/35572197
http://dx.doi.org/10.1016/j.omto.2022.04.001
work_keys_str_mv AT nielandlisa crisprcasknockoutofmir21reducesgliomagrowth
AT vansolingethomass crisprcasknockoutofmir21reducesgliomagrowth
AT cheahpikesee crisprcasknockoutofmir21reducesgliomagrowth
AT morsettlizam crisprcasknockoutofmir21reducesgliomagrowth
AT elkhouryjoseph crisprcasknockoutofmir21reducesgliomagrowth
AT rissmanjosephi crisprcasknockoutofmir21reducesgliomagrowth
AT kleinstiverbenjaminp crisprcasknockoutofmir21reducesgliomagrowth
AT broekmanmarikeld crisprcasknockoutofmir21reducesgliomagrowth
AT breakefieldxandrao crisprcasknockoutofmir21reducesgliomagrowth
AT abelserikr crisprcasknockoutofmir21reducesgliomagrowth